Search research articles
Contact Us
Filters
Showing results (151-160 of 225) with videos related to
Page
of 23
Sort By:
The Lancet. Microbe
|
December 4, 2025
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
Diane Gbesemete, Maheshi N Ramasamy, Muktar Ibrahim, et al.
The Lancet. Child & Adolescent Health
|
January 11, 2025
Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trial
Cherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
The Lancet. Microbe
|
March 26, 2026
Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study
Hans de Graaf, Diane F Gbesemete, Alison R Hill, et al.
The Pediatric Infectious Disease Journal
|
October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children
Carine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
Health Technology Assessment (Winchester, England)
|
May 19, 2025
Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
Cherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
The Lancet. Infectious Diseases
|
June 3, 2026
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
Frank Bähner, Saul N Faust, Leela R L Davies, et al.
Pneumonia (Nathan Qld.)
|
September 4, 2025
Changes in carriage and serotype diversity of Streptococcus pneumoniae and other respiratory pathobionts in the UK between pre-PCV13 (2006-10), early-PCV13 (2010-12) and late-PCV13 (2012-23) periods
David W Cleary, Rebecca Anderson, Jessica Jones, et al.
FEMS Microbiology Letters
|
September 1, 2017
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
Wynne D Smith, Emmanuelle Bardin, Loren Cameron, et al.
Science Translational Medicine
|
July 8, 2021
A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage
Jay R Laver, Diane Gbesemete, Adam P Dale, et al.
The Journal of Pediatrics
|
February 3, 2024
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial
David W Kimberlin, Inmaculada Aban, Kalyani Peri, et al.
Page
of 23
Search research articles
Search
Showing results (151-160 of 225) with videos related to
Sort By:
Page
of 23
The Lancet. Microbe
|
December 4, 2025
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
Diane Gbesemete, Maheshi N Ramasamy, Muktar Ibrahim, et al.
The Lancet. Child & Adolescent Health
|
January 11, 2025
Procalcitonin-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection in the UK (BATCH): a pragmatic, multicentre, open-label, two-arm, individually randomised, controlled trial
Cherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
The Lancet. Microbe
|
March 26, 2026
Safety, colonisation kinetics, transmissibility, and immune correlates of protection in healthy adults inoculated with Bordetella pertussis in England: a single-centre, open-label, phase 1, controlled human infection study
Hans de Graaf, Diane F Gbesemete, Alison R Hill, et al.
The Pediatric Infectious Disease Journal
|
October 17, 2018
Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children
Carine Claeys, Vijayalakshmi Chandrasekaran, José García-Sicilia, et al.
Health Technology Assessment (Winchester, England)
|
May 19, 2025
Effectiveness of biomarker-guided duration of antibiotic treatment in children hospitalised with confirmed or suspected bacterial infection: the BATCH RCT
Cherry-Ann Waldron, Philip Pallmann, Simon Schoenbuchner, et al.
The Lancet. Infectious Diseases
|
June 3, 2026
Safety and immunogenicity of mRNA-based mpox vaccine candidate BNT166a: an open-label, dose-escalation, first-in-human trial
Frank Bähner, Saul N Faust, Leela R L Davies, et al.
Pneumonia (Nathan Qld.)
|
September 4, 2025
Changes in carriage and serotype diversity of Streptococcus pneumoniae and other respiratory pathobionts in the UK between pre-PCV13 (2006-10), early-PCV13 (2010-12) and late-PCV13 (2012-23) periods
David W Cleary, Rebecca Anderson, Jessica Jones, et al.
FEMS Microbiology Letters
|
September 1, 2017
Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis
Wynne D Smith, Emmanuelle Bardin, Loren Cameron, et al.
Science Translational Medicine
|
July 8, 2021
A recombinant commensal bacteria elicits heterologous antigen-specific immune responses during pharyngeal carriage
Jay R Laver, Diane Gbesemete, Adam P Dale, et al.
The Journal of Pediatrics
|
February 3, 2024
Oral Valganciclovir Initiated Beyond 1 Month of Age as Treatment of Sensorineural Hearing Loss Caused by Congenital Cytomegalovirus Infection: A Randomized Clinical Trial
David W Kimberlin, Inmaculada Aban, Kalyani Peri, et al.
Page
of 23